Novartis takes option on Transgene's lung cancer immunotherapy
This article was originally published in Scrip
Executive Summary
Transgene of France has signed an exclusive option agreement with Novartis for the development and commercialisation of the targeted immunotherapy product TG4010 for the first-line treatment of non-small cell lung cancer (NSCLC) and other potential cancer indications.